Phase 2 study of Umbilical-cord-derived-mesenchymal-stem-cell-therapy-RESTEM in rheumatoid arthritis
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Umbilical cord derived mesenchymal stem cell therapy-RESTEM (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2025 New trial record
- 10 Jan 2025 According to RESTEM media release, company plans to initiate this trial in the second half of 2025.
- 10 Jan 2025 According to RESTEM media release, company received IND approval from the FDA for a Phase 2 study in rheumatoid arthritis